A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis

Exclusion Criteria

• •Psoriasis flare or rebound within 4 weeks prior to screening
• •Evidence of skin conditions, other than psoriasis, that would interfere with clinical assessments
• •Other than psoriasis, history of any clinically significant (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major uncontrolled disease
• •Prior history of suicide attempt at any time in the participant's lifetime prior to screening or baseline in the study, or major psychiatric illness requiring hospitalization within 3 years prior to signing the assent and informed consent
• •Guttate, erythrodermic, or pustular psoriasis at screening and baseline